Nuclear reprogramming of cells for therapeutic use

• US 20050058628A1
• Filed: 06/14/2004
• Published: 03/17/2005
• Est. Priority Date: 06/11/2003
• Status: Abandoned Application

• Current Assignee: Jan Remmereit
• Original Assignee: Jan Remmereit
• Inventors: Remmereit, Jan
• Application Number:
  US10/867,544
• Publication Number:
  US 20050058628A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: C12N 2502/00 Coculture with; Conditioned medium produced by
• CPC Class Codes: C12N 2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
• CPC Class Codes: C12N 5/16 Animal cells

Abstract

The present invention relates to cells that are reprogrammed by exposure to cytoplasm from other cells, and in particular to stem cells that are forced to adopt a particular fate by exposure to differentiated cell cytoplasm.

Claims

1. A composition comprising isolated stem cells and an extract of a differentiated cell line.

2. The composition of claim 1, wherein said isolated stem cells are human stem cells.

3. The composition of claim 1, wherein said isolated stem cells are non-human stem cells.

4. The composition of claim 1, wherein said extract of a differentiated cell line is derived from a neural cell line.

5. The composition of claim 1, wherein said extract of a differentiated cell line is derived from a hematopoietic cell line.

6. The composition of claim 1, wherein said extract of a differentiated cell line is derived from a mesenchymal cell line.

7. The composition of claim 1, wherein said extract of a differentiated cell line is derived from an endodermal cell line.

8. The composition of claim 1, wherein said extract of a differentiated cell line is derived from an ectodermal cell line.

9. The composition of claim 1, wherein said extract of a differentiated cell line is derived from a mesodermal cell line.

10. A method comprising:

a) providing isolated stem cells and an extract of a differentiated cell line;

b) treating said isolated stem cells with said extract of a differentiated cell line under conditions such that said isolated stem cells adopt a differential fate approximating the differential fate of said differentiated cell line.

11. The method of claim 10, wherein said isolated stem cells are human stem cells.

12. The method of claim 10, wherein said isolated stem cells are non-human stem cells.

13. The method of claim 10, wherein said extract of a differentiated cell line is derived from a neural cell line.

14. The method of claim 10, wherein said extract of a differentiated cell line is derived from a hematopoietic cell line.

15. The method of claim 10, wherein said extract of a differentiated cell line is derived from a mesenchymal cell line.

16. The method of claim 10, wherein said extract of a differentiated cell line is derived from an endodermal cell line.

17. The method of claim 10, wherein said extract of a differentiated cell line is derived from an ectodermal cell line.

18. The method of claim 10, wherein said extract of a differentiated cell line is derived from a mesodermal cell line.

19. The method of claim 10, wherein said treating further comprising permeabilizing said isolated cells.

20. Differentiated stem cells produced by the method of claim 10.

21. Organs comprising the differentiated stem cells of claim 20.

22. The method of claim 21, wherein said isolated stem cells are genetically modified.

23. A method comprising:

a) providing isolated cells, a stem cell extract, and a differentiated cell line extract;

b) treating said isolated cells with said stem extract under conditions such that said isolated cells are reprogrammed to an earlier differential fate; and

c) treating said reprogrammed cells with said differentiated cell line extract under conditions such that said reprogrammed cells adopt a differential fate approximating the differential fate of said differentiated cell line.

24. A method comprising:

a) providing isolated cells and a solution comprising telomerase or a nucleic acid encoding telomerase;

b) permeabilizing said isolated cells in said solution; and

c) culturing said isolated cells, wherein the telomers of said cells are lengthened.

25. The method of claim 24, wherein said isolated cells are human cells.

26. The method of claim 24, wherein said telomerase is human telomerase.

27. The method of claim 24, wherein said cells are genetically modified.

28. Cells produced by the method of claim 24.

29. Organs comprising the cells of claim 28.